Bimekizumab – Blocking of Both IL-17A and IL-17F: What Does It Mean for Us Dermatologists and Our patients?
The European Union’s approval of bimekizumab (BIMZELX®) for the treatment of moderate-to-severe plaque psoriasis on August 31st, 2021, has finally been cleared by Norway on November 22nd, 2022, making it the last country in Scandinavia to approve the product.
